Head-To-Head Analysis: Protalix BioTherapeutics (NYSE:PLX) versus Genocea Biosciences (NASDAQ:GNCAQ)

Protalix BioTherapeutics (NYSE:PLX) and Genocea Biosciences (NASDAQ:GNCAQ) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, risk, valuation, earnings, institutional ownership, analyst recommendations and profitability.

Earnings & Valuation

This table compares Protalix BioTherapeutics and Genocea Biosciences”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38 million	2.10	$8.31 million	$0.18	11.06
Genocea Biosciences	N/A	N/A	N/A	N/A	N/A

Protalix BioTherapeutics has higher revenue and earnings than Genocea Biosciences.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Protalix BioTherapeutics and Genocea Biosciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0	0	1	0	3.00
Genocea Biosciences	0	0	0	0	0.00

Protalix BioTherapeutics currently has a consensus price target of $12.00, suggesting a potential upside of 503.02%. Given Protalix BioTherapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Protalix BioTherapeutics is more favorable than Genocea Biosciences.

Institutional & Insider Ownership

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Protalix BioTherapeutics and Genocea Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
Genocea Biosciences	N/A	N/A	N/A

Risk & Volatility

Protalix BioTherapeutics has a beta of -0.02, indicating that its share price is 102% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.44, indicating that its share price is 144% more volatile than the S&P 500.

Summary

Protalix BioTherapeutics beats Genocea Biosciences on 6 of the 11 factors compared between the two stocks.

About Protalix BioTherapeutics

Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell-expressed recombinant PEGylated Uricase which is in Phase I trial for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate that is in preclinical phase for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is headquartered in Karmiel, Israel. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts. The plan was later approved as Chapter 11 liquidation on May 11, 2023.